Open Access

Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro

  • Wojciech Filipiak1, 2,
  • Andreas Sponring1, 2,
  • Tomas Mikoviny3,
  • Clemens Ager1, 2,
  • Jochen Schubert2, 4,
  • Wolfram Miekisch2, 4,
  • Anton Amann1, 2Email author and
  • Jakob Troppmair5Email author
Cancer Cell International20088:17

DOI: 10.1186/1475-2867-8-17

Received: 29 September 2008

Accepted: 24 November 2008

Published: 24 November 2008

Abstract

Background

The aim of this work was to confirm the existence of volatile organic compounds (VOCs) specifically released or consumed by lung cancer cells.

Methods

50 million cells of the human non-small cell lung cancer (NSCLC) cell line CALU-1 were incubated in a sealed fermenter for 4 h or over night (18 hours). Then air samples from the headspace of the culture vessel were collected and preconcentrated by adsorption on solid sorbents with subsequent thermodesorption and analysis by means of gas chromatography mass spectrometry (GC-MS). Identification of altogether 60 compounds in GCMS measurement was done not only by spectral library match, but also by determination of retention times established with calibration mixtures of the respective pure compounds.

Results

The results showed a significant increase in the concentrations of 2,3,3-trimethylpentane, 2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-methyloctane in the headspace of CALU-1 cell culture as compared to medium controls after 18 h. Decreased concentrations after 18 h of incubation were found for acetaldehyde, 3-methylbutanal, butyl acetate, acetonitrile, acrolein, methacrolein, 2-methylpropanal, 2-butanone, 2-methoxy-2-methylpropane, 2-ethoxy-2-methylpropane, and hexanal.

Conclusion

Our findings demonstrate that certain volatile compounds can be cancer-cell derived and thus indicative of the presence of a tumor, whereas other compounds are not released but seem to be consumed by CALU-1 cells.

Background

Analysis of exhaled breath for recognition of human diseases offers the possibility of non-invasive diagnosis [14]. This is particularly interesting for critically ill persons [5], as well as for large scale screening, in the case of renal and liver diseases [610] or for cancer [1117]. Exhaled air can be sampled as often as necessary without any restriction. It may even be done for newborn babies, or patients at the intensive care unit. Also on-line analysis of exhaled breath with continuous sampling and analysis of breath is possible [1821].

A particularly ambitious goal is a better understanding of the biochemical background of endogenous compounds appearing in exhaled breath, both for healthy persons and persons suffering from certain diseases like cancer. Many compounds observed in breath have never been discussed in connection with physiological biochemical processes. Compounds like 2,2-diethyl-1,1-biphenyl or 2-methyl-1-(1,1-dimethylethyl)-2-methyl-1,3-propanediyl propanoic acid ester have been detected [11], which are potentially interesting but whose underlying biochemistry is completely unknown.

Better known volatile compounds in exhaled breath are methanol, ethanol, acetone, acetaldehyde and isoprene. Even for these compounds, a detailed quantitative understanding of production, metabolization and excretion is not easily available. On-line analysis of exhaled breath under a challenge (a test on an ergometer with varying pulse and heart rate, ingestion of food etc.). are promising and will provide information leading to a better quantitative understanding of biochemical processes within the human body.

In the present contribution, we turn towards compounds appearing in exhaled breath of cancer patients. Lung cancer patients present a changed pattern of concentration for many volatile compounds. Some compounds appear in increased concentration in exhaled breath, some of them are decreased in concentration [1214]. For future cancer screening efforts it will be critical to know which of these compounds are effectively produced (or consumed) by cancer cells in the body. Other sources (and sinks) for volatile compounds are immuno-competent cells or microorganisms in the gut or the lung. These other sources are not considered here.

In the study presented here, we focus on a specific cancer cell line, CALU-1. In the future, we plan to extend our investigations to primary cells isolated by biopsies or in the course of a resection from patients themselves. This would allow a direct comparison of compounds released (or consumed) by cancer cells and the concentration patterns of volatile compounds in one and the same patient.

Methods

Cell Culture

As lung cancer cell line we tested the human, epithelial cell line CALU-1 which has been derived from a lung squamous cell carcinoma. This cell line builds numerous microvilli, a prominent rough endoplasmatic reticulum, lysosomes, and lipid inclusions. Furthermore, CALU-1 cells express a mutant K-ras gene. They are grown in DMEM high glucose (4.5 g/L) culture medium containing pyruvate (PAA) and supplemented with 10% FCS, penicillin (100 000 units/L), streptomycin (100 mg/L) and L-glutamine (293 mg/L). Cells were cultivated under standard conditions in a conventional incubator at 37°C in a humidified atmosphere with 92.5% air/7.5% CO2. For VOC measurements 50 millions trypsinized cells were inoculated in 100 ml phenol red free medium (DMEM high glucose) in a cell culture fermenter, flushed with clean, synthetic air taken from a gas cylinder (50 L defined gas mixture, Linde, Stadl-Paura, Austria) containing 5% CO2 for at least 10 min at a flow rate of 100 ml/min and sealed for 4 to 18 h. At the end of the incubation time 200 ml of air from the headspace was used for GC-MS analyses. Cell viability counts (trypan blue exclusion method) were performed at the end of the incubation period after.

Sampling

Glass tubes (Gerstel, Mülheim an der Ruhr, Germany) filled with the following sorbents were used as traps for sample collection with simultaneous preconcentration: 25 mg Tenax TA (60/80 mesh), 35 mg Carboxen 569 (20/45 mesh), 250 mg Carboxen 1000 (80/100 mesh) (each from Supelco, Bellefonte, PA, USA). Sorbents were separated by glass wool. The sampled air was diluted 1:6 with dry and additionally purified synthetic air to avoid excess humidity for thermodesorption. The volume of collected sample originating from the fermenter was 200 ml with a total flow through sorption trap of 30 ml/min.

Thermal desorption

The sampled analytes were released from sorbents by thermal desorption in the TDS3 unit equipped with a TDSA2 auto sampler (both from Gerstel, Mülheim an der Ruhr, Germany). The flow rate of carrier gas through the sorption trap during desorption was 90 ml/min. The initial temperature was 30°C and was increased to 300°C by a heating rate of 100°C/min (held for 10 min). Liquid nitrogen was used for cryofocusing the desorbed analytes (-90°C). For subsequent sample injection into the capillary column the CIS-4 injector which contained the glass liner filled with Carbotrap B (Gerstel, Mülheim an der Ruhr, Germany) was heated with the rate 12°C/sec up to 320°C (hold 2 min in splitless mode).

GC-MS analyses

The TD-GC-MS analyses were performed on a 6890N gas chromatograph equipped with a mass selective detector 5973N (both from Agilent Technologies, Waldbronn, Germany) with sample injection by means of thermal desorption (described in previous sections). The MS analyses were performed in a full scan mode, with a scan range of 20–200 amu. Ionization of the separated compounds was done by electron impact ionization at 70eV. The acquisition of the chromatographic data was performed by means of the Agilent Chemstation Software (GC-MS Data Analysis from Agilent, Waldbronn, Germany) and the mass spectrum library NIST 2005 (Gatesburg, USA) was applied for identification. The PoraBond Q capillary column 25 m × 0,32 mm × 5 μm (Varian, Palo Alto, CA, USA) was used. The oven temperature program was as follows: initial 50°C held for 5 min, then ramped 5°C/min up to 140°C held 5 min, again ramped 5°C/min to 280°C and held for 4 min. The constant flow rate of helium as a carrier gas was 2 ml/min.

Reagents and standards

2-Butanone, acrolein, methacrolein, 2-ethylacrolein, 2-methylpropanal, 3-methylbutanal, 2-methylbutanal, 2-methyl-2-butenal, hexanal, n-butyl acetate, methyl tert-butyl ether, ethyl tert-butyl ether, 2,4-dimethylpentane, 2,3,4-trimethylpentane, decane and tetrahydrofuran were each purchased from Sigma-Aldrich (Sigma-Aldrich, Steinheim, Germany). 2,3,3-Trimethylpentane, 2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-methyloctane were purchased from ChemSampCo (ChemSampCo, LLC, Trenton, New Jersey, USA), acetaldehyde was purchased from Acros Organics (Acros Organics, Geel, Belgium) and acetonitrile was purchased from J.T. Baker (Mallinckrodt Baker B.V., Deventer, The Netherlands).

Calibration

For quantification of compounds detected in headspace of cells and medium solutions the external standard calibration was performed. Preparation of gaseous standards was performed by evaporation of liquid substances in glass bulbs. Each bulb (Supelco, Bellefonte, PA, USA) was cleaned with methanol (Sigma-Aldrich, Steinheim, Germany), dried at 85°C for at least 20 hours, purged with clean nitrogen for at least 20 min and subsequently evacuated using a vacuum pump (Vacuubrand, Wertheim, Germany) for 30 minutes. Liquid standards (1–3 μL according to desired concentration) were injected through a septum, using a GC syringe. After the evaporation of standards the glass bulb was filled with nitrogen of purity 6.0 (i.e. 99,9999%, Linde, Vienna, Austria) in order to equalize the pressure (to the ambient pressure). Then the appropriate volume [μL] of vapour mixture was transferred using a gas tight syringe (Hamilton, Bonaduz, Switzerland) into Tedlar® bags (SKC 232 Series, Eighty Four, PA, USA, SKC 232 Series) previously filled with 1,5 L of nitrogen (99,9999%) additionally purified by means of carbon molecular sieves (Carboxen 1000).

Results

Identification and quantification of VOCs released by CALU-1 cells

Viability after incubation of 50 millions of cells for 4 hours was 98.6 ± 1.1% and after incubation for 18 h 98.7 ± 0.7%. Thus, almost no cell death was caused under the given conditions which ensures that the release of potential VOCs is mostly due to living and not dying cells.

Among all detected compounds we observed altogether 60 substances that could be identified not only by spectral library match using NIST 2005 library but also by determination of retention time based on calibration mixtures of the respective pure compound (Table 1A). An exemplary chromatogram of the headspace of CALU-1 cancer cells is presented in Figure 1. The substances, for which identification was done only by means of spectral library match without confirmation of their retention times, are listed in Table 1B. The peaks for which the proper identification was not possible (too low library match and no confirmation by retention time) are not discussed at all. Generally, the applied TD-GC-MS method is characterized by good linearity (even for the lowest detected concentrations) with correlation coefficients being mostly higher than 0,99. The LODs for almost all compounds were as low as pptv level. The lowest LOD was observed for 2,3,3-trimethylpentane (127 pptv = 5,725*10-4 μg/l) and 2,3,5-trimethylhexane (137 pptv = 7,583*10-4 μg/l) but also polar compounds exhibited very low detection limits, e.g. 2-methylpropanal (143 pptv = 3,912*10-4 μg/l) and acetonitrile (147 pptv = 1,166*10-7 μg/l). Only two compounds of interest with LOD at the level of single ppbv (the highest observed values) were acetaldehyde (1,517 ppbv = 1,312*10-3 μg/l), and 4-methyloctane (1,168 ppbv = 5,578*10-3 μg/l). More detailed informations are listed in Tables 2 and 3A-B). Such low limits of detection with simultaneous low errors (expressed by correlation coefficients) testify very good precision and sensitivity of the applied TD-GC-MS method.
Figure 1

An exemplary chromatogram of volatile compounds in headspace of the cancer cells CALU-1. 200 ml of headspace from cells cultured in 100 ml medium were collected on a sorption trap filled with Tenax TA, Carboxen 569, Carboxen 1000 and subsequently thermal desorbed into the GC-MS system. The peaks that correspond to compounds discussed in this paper are labeled with letters (see Table 1). Peaks exceeding the range of scale are cut off.

Table 1

A: Summary of all substances identified by spectral match and confirmation of retention time

No.

Compound

tR [min]

CAS

 

1

Methyl alcohol

8,778

67-56-1

 

2

Dimethyl ether

10,323

115-10-6

 

3

Acetaldehyde

11,936

75-07-0

 

4

Methanethiol

13,130

74-93-1

 

5

Isobutane

15,785

75-28-5

 

6

2-Methyl-1-propene

16,118

115-11-7

 

7

Ethyl alcohol

16,517

64-17-5

 

8

Acetonitrile (a)

17,423

75-05-8

 

9

2-Butene (Z or E isomer)

17,009

107-01-7

 

10

Butane

17,186

106-97-8

 

11

2-Butene (E or Z isomer)

17,360

115-11-7

 

12

2-Propenal (b)

19,310

107-02-8

 

13

Furan

19,741

110-00-9

 

14

Propanal

20,170

123-38-6

 

15

Acetone

20,469

67-64-1

 

16

Isopropyl Alcohol

21,720

67-63-0

 

17

2-Methylbutane

23,229

78-78-4

 

18

Ethyl ether

23,503

60-29-7

 

19

1-Propanol

23,696

71-23-8

 

20

Pentane

24,224

109-66-0

 

21

Methacrolein (c)

25,375

78-85-3

 

22

2-Methylpropanal (d)

25,917

78-84-2

 

23

Methyl vinyl ketone

26,795

78-94-4

 

24

Trichloromethane

27,561

67-66-3

 

25

Tetrahydrofuran

27,920

109-99-9

 

26

2-Butanone (e)

28,124

78-93-3

 

27

Ethyl acetate

29,829

141-78-6

 

28

2-Methoxy-2-methylpropane (f)

30,377

1634-04-4

 

29

2-Methyl-1-pentene

31,692

763-29-1

 

30

Benzene

32,418

71-43-2

 

31

Hexane

33,003

110-54-3

 

32

2-Ethylacrolein

34,049

922-63-4

 

33

3-Methylbutanal (g)

34,587

590-86-3

 

34

2-Ethoxy-2-methylpropane (h)

35,346

637-92-3

 

35

2-Pentanone

35,868

107-87-9

 

36

Methyl methacrylate

36,121

80-62-6

 

37

2-Methyl-2-butenal

37,277

1115-11-3

 

38

3-Methylhexane

38,434

589-34-4

 

39

Cyclopentanone

38,750

120-92-3

 

40

Toluene

39,466

108-88-3

 

41

Furfural

40,044

98-01-1

 

42

Methyl isobutyl ketone

40,262

108-10-1

 

43

Hexanal (i)

42,001

66-25-1

 

44

Butyl acetate (j)

42,624

123-86-4

 

45

2,3,4-Trimethylpentane

42,949

565-75-3

 

46

2,3,3-Trimethylpentane (k)

43,202

560-21-4

 

47

4-Methylheptane

43,385

589-53-7

 

48

3-Ethylhexane

43,580

619-99-8

 

49

Octane

44,465

111-65-9

 

50

p-Xylene

44,721

106-42-3

 

51

Styrene

45,195

100-42-5

 

52

p-Xylene

45,363

106-42-3

 

53

3-Methyl-2(5H)-furanone

45,779

22122-36-7

 

54

2,3,5-Trimethylhexane (l)

46,456

1069-53-0

 

55

2,4-Dimethylheptane (m)

46,647

2213-23-2

 

56

Benzaldehyde

46,799

100-52-7

 

57

4-Methyloctane (n)

47,697

2216-34-4

 

58

Octanal

50,921

124-13-0

 

59

Limonene

52,217

138-86-3

 

60

Decane

52,572

124-18-5

 

Listed are substances observed in the headspace of medium as well as in the headspace of CALU-1 cancer cells. Letters in parentheses refer to peaks shown in the chromatogram of Figure 1.

B: List of compounds identified only by means of spectral library match

 

Compound

t R [min]

CAS

M +.

 

Propene

7,939

115-07-1

42

 

Chloromethane

8,259

74-87-3

50

 

Acetophenone

51,165

98-86-2

120

 

(1E)-1-Butenylbenzene

53,069

824-90-8

132

 

Nonanal

54,630

124-19-6

144

Listed are compounds detected in the headspace of medium and CALU-1 cancer cells. Relative molecular mass (RMM) of the suspected molecular ion is given for each presented compound.

Table 2

Quantification of VOCs released from CALU-1 cancer cells after adsorption on solid sorbents with subsequent TD-GC-MS analyses.

    

Concentration [ppbv] after 18 hours of incubation

mean ppb Medium

mean ppb Cells

ppb Cells/ppb Medium

Compound

CAS

R2

LOD [ppbv]

Medium

Cells

   

2,3,3-trimethylpentane

560-21-4

0,998

0,127

0,37

0,45

0,40

0,60

0,84

0,86

0,41

0,77

1,89

2,3,5-trimethylhexane

1069-53-0

0,997

0,149

0,43

0,42

0,29

0,79

0,67

0,50

0,38

0,65

1,71

2,4-dimethylheptane

2213-23-2

0,996

0,179

0,33

0,35

0,20

1,25

0,77

0,65

0,29

0,89

3,04

4-methyloctane

2216-34-4

0,985

1,168

1,33

1,51

2,02

4,03

2,09

2,17

1,62

2,76

1,71

The concentrations of these VOCs are increased in headspace of CALU-1 cells in comparison with medium only, after 18 hours of incubation. The concentrations of discussed VOCs are given for each measured sample (headspace of CALU-1 cells and of medium). The correlation coefficients (for calibration experiments) and the limits of detection (LODs) are presented.

TD-GC-MS analyses of the headspace of CALU-1 cells

In three independent experiments using TD-GC-MS after preconcentration of sampled air by means of adsorption on solid sorbents, the concentrations of 4 compounds could be shown to be increased (Table 2) and other 12 compounds to be decreased (Table 3A and 3B) in the headspace of CALU-1 cells as compared to the headspace of medium only. These compounds are those which were detected in all measured samples of cancer cells as well as medium. All other 44 (= 60-16) identified compounds are not discussed in detail since they appeared "irregularly", i.e., not consistently increased or decreased with respect to medium only. The only exception is 2-methyl-2-butenal which was always found > LOD in cell culture medium samples whereas its concentration was below LOD in every CALU1 cell sample. Because of the big variations and small sample population, statistical tests should not be used. Instead, the direct comparison of VOCs concentration detected in cell and medium samples was done. We discuss only those compounds which are present in every CALU1 cell sample at (consistently) higher or (consistently) lower level than in every medium sample. Ratios of mean concentrations from both kinds of samples are given in Tables 2 and 3A–B.
Table 3

A and B: Quantification of VOCs consumed by CALU-1 cancer cells after adsorption on solid sorbents with subsequent TD-GC-MS analyses.

A

              
    

Concentration [ppbv] after 4 hours of incubation

mean ppb Medium

mean ppb Cells

ppb Cells/ppb Medium

Compound

CAS

R2

LOD [ppbv]

Medium

Cells

   

methacrolein

78-85-3

0,999

0,466

5,66

9,38

3,93

0,63

0,34

0,84

0,34

0,34

4,898

0,469

0,10

2-methylpropanal

78-84-2

0,998

0,143

19,80

12,98

39,53

9,12

1,21

below LOD

3,35

2,03

20,357

1,649

0,08

methyl tert-butyl ether

1634-04-4

0,999

0,293

1,68

3,43

3,56

1,60

0,67

0,94

1,30

1,11

2,567

1,004

0,39

3-methylbutanal

590-86-3

0,994

0,234

142,29

184,19

218,74

73,14

0,08

2,44

3,02

2,13

154,588

1,916

0,01

n-butyl acetate

123-86-4

0,999

0,134

60,47

105,13

66,58

58,08

2,01

14,70

11,27

13,08

72,566

10,267

0,14

B

              

Compound

CAS

R 2

LOD [ppb v ]

Concentration [ppb v ] after 18 hours of incubation

mean ppb Medium

mean ppb Cells

ppb Cells/ppb Medium

     

Medium

Cells

    

acetaldehyde

75-07-0

0,993

1,517

257,527

335,818

315,063

 

below LOD

116,472

81,692

 

302,803

66,054

0,22

acetonitrile

75-05-8

0,998

0,147

11,344

7,540

5,764

 

4,183

3,633

4,100

 

8,216

3,972

0,48

acrolein

107-02-8

0,998

0,718

5,703

3,462

4,079

 

2,185

2,071

3,238

 

4,415

2,498

0,57

methacrolein

78-85-3

0,999

0,466

5,933

4,975

4,723

 

0,811

0,344

0,702

 

5,210

0,619

0,12

2-methylpropanal

78-84-2

0,998

0,143

30,915

11,773

21,277

 

0,532

3,573

0,083

 

21,322

1,396

0,07

2-butanone

78-93-3

0,999

0,149

3,523

5,206

3,084

 

1,114

2,812

1,669

 

3,938

1,865

0,47

methyl tert-butyl ether

1634-04-4

0,999

0,293

2,126

4,202

2,089

 

0,753

1,654

1,023

 

2,806

1,143

0,41

3-methylbutanal

590-86-3

0,994

0,234

157,462

206,895

78,027

 

2,226

2,215

1,529

 

147,461

1,990

0,01

ethyl tert-butyl ether

637-92-3

0,999

0,215

6,168

11,281

5,121

 

2,060

4,805

2,229

 

7,523

3,032

0,40

2-methyl-2-butenal

1115-11-3

0,985

0,430

1,839

1,024

1,163

 

below LOD

below LOD

below LOD

 

1,342

0,000

0,00

hexanal

66-25-1

0,981

0,540

2,043

2,805

1,980

 

0,791

1,016

0,711

 

2,276

0,839

0,37

n-butyl acetate

123-86-4

0,999

0,134

43,949

31,381

26,348

 

11,084

3,032

3,324

 

33,892

5,813

0,17

The concentration of these VOCs is decreased in headspace of CALU-1 cells in comparison with medium only. Two different incubation times were studied: 4 h (A) and 18 h (B). The concentrations of discussed VOCs are given for measured sample (headspace of CALU-1 cells and of medium). The correlation coefficients (for calibration experiments) and the limits of detection (LODs) are presented.

After 4 hours of incubation in the fermenter an increase of isopropyl alcohol could be found. However, concentration of 2-propanol increased in only 3 from 4 measurements with 4 h incubation, whereas for the samples incubated 18 h there is no significant difference between the measured amount of 2-propanol in headspace of cancer cells and in headspace of medium. After 18 h of incubation 2,3,3-trimethylpentane (mean ppbv in cells/mean ppbv in medium = 1,89), 2,3,5-trimethylhexane (1,71), 2,4-dimethylheptane (3,04) and 4-methyloctane (1,71) were increased significantly in the headspace of CALU-1 cells (Figure 2). Decreased concentrations from cancer cells after 4 h were found for the compounds methacrolein (0,10), 2-methylpropanal (0,08), 2-methoxy-2-methylpropane (0,39), 3-methylbutanal (0,01), 2-methyl-2-butenal (0) and n-butyl acetate (0,14) (Figure 3 and Figure 4A). After 18 h of incubation acetaldehyde (mean ppbv in cells/mean ppbv in medium = 0,22), acetonitrile (0,48), acrolein (0,57), methacrolein (0,12), 2-methylpropanal (0,07), 2-butanone (0,47), 2-methoxy-2-methylpropane (0,41), 3-methylbutanal (0,01), 2-methyl-2-butenal (0), 2-ethoxy-2-methylpropane (0,40), hexanal (0,37) and n-butyl acetate (0,17) were decreased significantly (Figure 3 and Figure 4B).
Figure 2

Comparison of VOCs concentrations present at higher concentration in the headspace of CALU-1 cells in culture (blue columns) as compared to medium control (red columns) after 18 h of incubation. Presented are average concentrations (n = 3) with standard deviations. Significant differences are labeled with asterisks.

Figure 4

A and B: Comparison of VOCs concentrations present at lower level in the headspace of cell culture (CALU-1) solution (blue columns) as compared with medium only (red columns) after 4 h (Fig. 4A) and 18 h (Fig. 4B) of incubation. Presented are average concentrations (n = 4 for 4 h of incubation, n = 3 for 18 h of incubation) with standard deviation. Significant differences are labeled with asterisks.

Discussion

In our experiments VOCs released from the lung cancer cell line CALU-1 were collected and preconcentrated by means of adsorption on solid sorbents with subsequent thermal desorption and analysis by GC-MS. In investigations with the cell line CALU-1 longer and shorter incubation times (18 h and 4 h respectively) were tested whereas in earlier experiments a technical device and a protocol for this experimental setting had to be developed.

The results of experiments with CALU-1 cells confirmed the existence of compounds that are either released or consumed by these cells. Discussed are only these analytes which were detected in all samples of medium as well as cancer cells. Furthermore, it is indicated that the release of compounds can be detected after prolonged incubation time but so far no significant release after 4 hours of incubation could be observed. On the other hand, consumption of several aldehydes as well as n-butyl acetate and methyl tert-butyl ether from the headspace of cells solution could be detected already after a short period of incubation. Even for the compounds like acetaldehyde and especially 3-methylbutanal and n-butyl acetate that are based on high background from medium, a strong reduction of concentration was observed after only 4 hours of incubation (Table 3A). The influence of incubation time on the amount of detected compounds is illustrated in Figure 3. Because of big variations in measured peak areas of acetaldehyde the significance for this compound was not confirmed after 4 h incubation, although a tendency can be observed.
Figure 3

Comparison of VOCs present at lower concentrations present in the headspace of cells in culture (CALU-1) (bright blue and dark blue columns) as compared to medium control (yellow and red columns) after 4 h and 18 h of incubation. Presented are average concentrations (n = 4 for 4 h of incubation, n = 3 for 18 h of incubation) with standard deviations. Significant differences are labeled with asterisks.

Interestingly, the results of our experiments showed that the majority of detected volatile substances which are significantly increased in the headspace of cell culture compared to medium control are saturated hydrocarbons. From CALU-1 cells 2,3,3-trimethylpentane, 2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-methyloctane were released (Figure 2). The measured concentrations of these compounds are listed in Table 2. In the group of Phillips et al. it was found that several alkanes and branched hydrocarbons including also 4-methyloctane were increased in the breath of lung cancer patients compared to healthy persons [12, 13].

Because of the high concentrations of target compounds in the medium, the difference between their amount in cell and in medium headspace samples is rather low. Moreover, although release of some compounds seems to be observed, background peak areas are considerably different in independent experiments which results in high standard deviation. Thus direct comparison of measured amounts is not precise. The compounds already present in the headspace of culture medium may, in particular, originate from fetal calf serum added to culture medium. Thus, to reduce background one option would be to use medium without serum or to reduce serum to low concentrations. However, preliminary experiments indicated a loss of VOC release under low serum cell culture conditions, possibly due to different metabolism of the cell line used. Thus to achieve lower background level we reduced fetal calf serum but only to 5%.

The metabolic origin of the detected substances so far remains speculative. In the present experiments we observed saturated as well as branched hydrocarbons, which corroborates clinical studies which demonstrate exhalation of hydrocarbons.

We observed that acetaldehyde is consumed by CALU-1 cells (Figure 3). This fact is contradictory to the work of Smith et al. who found increased concentrations of acetaldehyde released from CALU-1 and SK-MES cells, also a lung cancer cell line [22]. The reason or reasons for this completely opposite behavior of CALU-1 cells, concerning the metabolism of acetaldehyde are unclear. In literature acetaldehyde is described as the first metabolic product of alcohol metabolism in vivo [23] and as carcinogenic.

Besides acetaldehyde several other compounds are consumed or taken up by the cells whereby especially aldehydes have decreased concentrations compared to medium control (see Table 3A and 3B and Figures 4A and 4B). As for acetaldehyde the mechanism of consumption of those substances by the cells has to be elucidated. However, the degradation or consumption of aldehydes may be partly explained by an increased activity of aldehyde dehydrogenases. For instance, aldehyde dehydrogenase 1 was found to be a marker of breast cancer cells [24] and was found to be increased in the lung cancer cell line A549 [25]. Moreover, in a work of Patel et al. [26] significantly higher expression levels of aldehyde dehydrogenase 1A1 and aldehyde dehydrogenase 3A1 were detected in squamous cell cancer, adenocarcinoma, and small cell lung cancer. In this work it was shown that atypical pneumocytes demonstrated significantly higher levels of expression of aldehyde dehydrogenase 1A1 and aldehyde dehydrogenase 3A1 than normal pneumocytes (a normal counterpart of adenocarcinoma), which is suggestive of up regulation during malignant transformation to adenocarcinoma. It was also found that non-small cell lung cancer expresses very high levels of aldehyde dehydrogenase 1A1 and aldehyde dehydrogenase 3A1 in comparison with small cell lung cancer. Thus, elevated expression of both enzymes may be associated with malignant transformation to adenocarcinoma. Those data would point out a putative metabolic mechanism of degradation of aldehydes which was observed in this work.

Conclusion

This work is a first step to get a better understanding on the metabolism of VOCs from cancer cells. We found that 2,3,3-trimethylpentane, 2,3,5-trimethylhexane, 2,4-dimethylheptane and 4-methyloctane are released from the cell line CALU-1 and therefore should be taken into account as possible tumor-related compounds. It was also clearly shown that these cells are consuming several types of aldehydes but also compounds from other classes. Decreased level of aldehydes can be partly explained by higher activity of aldehyde dehydrogenase in cancer cells. Summarizing, these investigations give some hints which substances are candidates for biomarkers of cancer disease and thus may finally provide a technically feasible method for early and non-invasive diagnosis of lung cancer. However, biochemical background of all discussed compounds should be elucidated before using them as fully assured biomarkers.

Declarations

Acknowledgements

This project has been supported by the European Commission (project BAMOD, project No LSHC-CT-2005-019031). and the Austrian Ministry for Science and Research (BMWF, Vienna, Austria, grants GZ 651.019/1-VI/2/2006, GZ 651.019/3-VI/2/2006). We greatly appreciate the generous support of the Member of the Tyrolean regional government Dr. Erwin Koler and the Director of the University Clinic of Innsbruck (TILAK) Mag. Andreas Steiner.

Authors’ Affiliations

(1)
Department of Operative Medicine, Innsbruck Medical University Anichstr. 35
(2)
Breath Research Unit of the Austrian Academy of Sciences
(3)
Institute for Ion Physics, Leopold-Franzens University of Innsbruck
(4)
Department of Anesthesiology and Intensive Care, University of Rostock
(5)
Daniel-Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, Innsbruck Medical University

References

  1. Amann A, Smith D, (eds): Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. 2005, Singapore: World ScientificGoogle Scholar
  2. Amann A, Spanel P, Smith D: Breath analysis: the approach towards clinical applications. Mini Rev Med Chem. 2007, 7 (2): 115-129.View ArticlePubMedGoogle Scholar
  3. Schubert J, Miekisch W, Nöldge-Schomburg G: VOC breath markers in critically ill patients: potentials and limitations. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Edited by: Amann A, Smith D. 2005, Singapore: World Scientific, 267-292.View ArticleGoogle Scholar
  4. Risby T: Current status of clinical breath analysis. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Edited by: Amann A, Smith D. 2005, Singapore: World Scientific, 251-265.View ArticleGoogle Scholar
  5. Schubert JK, Miekisch W, Geiger K, Noldge-Schomburg GF: Breath analysis in critically ill patients: potential and limitations. Expert Rev Mol Diagn. 2004, 4 (5): 619-629.View ArticlePubMedGoogle Scholar
  6. Davies S, Spanel P, Smith D: A new 'online' method to measure increased exhaled isoprene in end-stage renal failure. Nephrol Dial Transplant. 2001, 16 (4): 836-839.View ArticlePubMedGoogle Scholar
  7. Davies S, Spanel P, Smith D: Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Kidney Int. 1997, 52 (1): 223-228.View ArticlePubMedGoogle Scholar
  8. Davies SJ, Spanel P, Smith D: Quantitative analysis of metabolites on the breath of patients in renal failure. Journal of the American Society of Nephrology. 1996, 7 (9): A0352-A0352.Google Scholar
  9. Perri F, Marras RM, Ricciardi R, Quitadamo M, Andriulli A: 13C-breath tests in hepatology (cytosolic liver function). Eur Rev Med Pharmacol Sci. 2004, 8 (1): 47-49.PubMedGoogle Scholar
  10. Candelli M, Armuzzi A, Nista EC, Fini L, Gasbarrini G, Gasbarrini A: 13C-methacetin breath test for monitoring hepatic function in cirrhotic patients before and after liver transplantation. Aliment Pharmacol Ther. 2004, 19 (2): 243-View ArticlePubMedGoogle Scholar
  11. Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P: Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark. 2007, 3 (2): 95-109.PubMedGoogle Scholar
  12. Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN: Detection of lung cancer with volatile markers in the breath. Chest. 2003, 123 (6): 2115-2123.View ArticlePubMedGoogle Scholar
  13. Phillips M, Cataneo RN, Ditkoff BA, Fisher P, Greenberg J, Gunawardena R, Kwon CS, Rahbari-Oskoui F, Wong C: Volatile markers of breast cancer in the breath. Breast J. 2003, 9 (3): 184-191.View ArticlePubMedGoogle Scholar
  14. Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl G, Amann A: Lung cancer detection by proton transfer reaction mass spectrometric analysis of human breath gas. Int J Mass Spec. 2007, 265: 49-59.View ArticleGoogle Scholar
  15. Machado RF, Laskowski D, Deffenderfer O, Burch T, Zheng S, Mazzone PJ, Mekhail T, Jennings C, Stoller JK, Pyle J, Duncan J, Dweik RA, Erzurum SC: Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med. 2005, 171 (11): 1286-1291.PubMed CentralView ArticlePubMedGoogle Scholar
  16. Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni C, Finazzi-Agro A, D'Amico A: Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron. 2003, 18 (10): 1209-1218.View ArticlePubMedGoogle Scholar
  17. Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A: Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 2005, 6 (1): 71-PubMed CentralView ArticlePubMedGoogle Scholar
  18. Amann A, Telser S, Hofer L, Schmid A, Hinterhuber H: Exhaled breath as a biochemical probe during sleep. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Edited by: Amann A, Smith D. 2005, Singapore: World Scientific, 305-316.View ArticleGoogle Scholar
  19. Smith D, Spanel P: On-line determination of the deuterium abundance in breath water vapour by flowing afterglow mass spectrometry with applications to measurements of total body water. Rapid Commun Mass Spectrom. 2001, 15 (1): 25-32.View ArticlePubMedGoogle Scholar
  20. Smith D, Spanel P: On-line determination of the deuterium abundance in breath water vapour by flowing afterglow mass spectrometry, FA-MS, with applications to measurements of total body water. Rapid Commun Mass Spectrom. 2001, 15 (1): 25-32.View ArticlePubMedGoogle Scholar
  21. Smith D, Wang TS, Spanel P: On-line, simultaneous quantification of ethanol, some metabolites and water vapour in breath following the ingestion of alcohol. Physiological Measurement. 2002, 23 (3): 477-489.View ArticlePubMedGoogle Scholar
  22. Smith D, Wang T, Sule-Suso J, Spanel P, Haj AE: Quantification of acetaldehyde released by lung cancer cells in vitro using selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom. 2003, 17 (8): 845-850.View ArticlePubMedGoogle Scholar
  23. Homann N: Alcohol and upper gastrointestinal tract cancer: the role of local acetaldehyde production. Addiction biology. 2001, 6 (4): 309-323.View ArticlePubMedGoogle Scholar
  24. Balicki D: Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007, 1 (5): 485-487.View ArticlePubMedGoogle Scholar
  25. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH, Yoo YJ: Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun. 2001, 289 (2): 507-512.View ArticlePubMedGoogle Scholar
  26. Patel M, Lu L, Zander DS, Sreerama L, Coco D, Moreb JS: ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008, 59 (3): 340-349.View ArticlePubMedGoogle Scholar

Copyright

© Filipiak et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement